scholarly journals Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria

2011 ◽  
Vol 34 (8) ◽  
pp. 935-941 ◽  
Author(s):  
Masanori Abe ◽  
Noriaki Maruyama ◽  
Kazuyoshi Okada ◽  
Shiro Matsumoto ◽  
Koichi Matsumoto ◽  
...  
Keyword(s):  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Diabetic Patients ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic Patients ◽  
Antioxidative Effects ◽  
Type 2 Diabetic

scholarly journals Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria

2012 ◽  
Vol 35 (8) ◽  
pp. 874-881 ◽  
Author(s):  
Masanori Abe ◽  
Noriaki Maruyama ◽  
Hiroko Suzuki ◽  
Yuki Fujii ◽  
Midori Ito ◽  
...  
Keyword(s):  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Angiotensin Receptor Blocker ◽  
Channel Blocker ◽  
Receptor Blocker ◽  
Diabetic Patients ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

scholarly journals Diabetic Nephropathy in Spontaneously Type 2 Diabetic Nonhuman Primates (Rhesus Monkeys Macaca mulatta ): Comparator Validation of Angiotensin Receptor Blocker Valsartan

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Barbara Caleen Hansen ◽  
Zunyuan Yang ◽  
Yinan Liang ◽  
Zunwei Yao ◽  
Licai Zeng ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Macaca Mulatta ◽  
Rhesus Monkeys ◽  
Angiotensin Receptor Blocker ◽  
Nonhuman Primates ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic

scholarly journals Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria

Diabetes Care ◽  
2011 ◽  
Vol 34 (9) ◽  
pp. 2078-2083 ◽  
Author(s):  
Merel E. Hellemons ◽  
Frederik Persson ◽  
Stephan J.L. Bakker ◽  
Peter Rossing ◽  
Hans-Henrik Parving ◽  
...  
Keyword(s):  
Renal Outcome ◽  
Diabetic Patients ◽  
Receptor Blockade ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic Patients ◽  
Angiotensin Receptor Blockade ◽  
Type 2 Diabetic

Effect of Combination Therapy with Angiotensin Receptor Blocker and 1,25-Dihydroxyvitamin D3 in Type 2 Diabetic Nephropathy in KK-Ay/Ta Mice

2011 ◽  
Vol 117 (4) ◽  
pp. 124-132 ◽  
Author(s):  
Ikko Ohara ◽  
Mitsuo Tanimoto ◽  
Tomohito Gohda ◽  
Takahiko Yamazaki ◽  
Shinji Hagiwara ◽  
...  
Keyword(s):  
Diabetic Nephropathy ◽  
Combination Therapy ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Angiotensin Receptor ◽  
Dihydroxyvitamin D3 ◽  
1,25 Dihydroxyvitamin D3 ◽  
Type 2 Diabetic

scholarly journals The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice

2016 ◽  
Vol 76 ◽  
pp. 28-36 ◽  
Author(s):  
Kathryn E. Husarek ◽  
Paige S. Katz ◽  
Aaron J. Trask ◽  
Maarten L. Galantowicz ◽  
Mary J. Cismowski ◽  
...  
Keyword(s):  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Diabetic Mice ◽  
Angiotensin Receptor ◽  
Type 2 Diabetic

scholarly journals Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease

Diagnostics ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 207
Author(s):  
Ming-Hsien Wu ◽  
Chia-Ni Lin ◽  
Daniel Tsun-Yee Chiu ◽  
Szu-Tah Chen
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Angiotensin Receptor Blocker ◽  
Receptor Blocker ◽  
Plasma Metabolites ◽  
Diabetic Patients ◽  
Angiotensin Receptor ◽  
Variable Response ◽  
Type 2 Diabetic Patients ◽  
Diabetic Kidney

Albuminuria is a measurement and determinant factor for diabetic kidney disease (DKD). Angiotensin receptor blocker (ARB) is recommended for albuminuria in DKD with variable response. To find surrogate markers to predict the therapeutic effect of ARB, we carried out a prospective study to correlate plasma metabolites and the progression of renal function/albuminuria in DKD patients. A total of 56 type 2 diabetic patients with various stages of chronic kidney disease and albuminuria were recruited. ARB was prescribed once albuminuria was established. Urinary albumin-to-creatinine ratio (UACR) was determined before and six months after ARB treatment, with a ≥30% reduction of UACR considered an ARB responder. Plasma levels of 145 metabolites were measured before ARB treatment; only those associated with albuminuria were selected and compared between ARB responders and non-responders. Both lower tryptophan (Trp ≤ 46.75 μmol/L) levels and a higher kynurenine/tryptophan ratio (KTR ≥ 68.5 × 10−3) were significantly associated with macroalbuminuria (MAU), but only KTR (≥54.7 × 10−3) predicts ARB responsiveness (sensitivity 90.0%, specificity 50%) in MAU. Together, these data suggest that the kynurenine/tryptophan ratio predicts angiotensin receptor blocker responsiveness in patients with diabetic kidney disease.

Sign in / Sign up

Export Citation Format

Share Document